Advertisement

Topics

Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee

11:21 EDT 10 Aug 2018 | Forbes

This morning, after 16 years and $2.5 billion in investment, the Cambridge, Mass.-based company Alnylam finally turned a 1998 biology breakthrough into a medicine: a drug called Onpattro to treat the destruction of nerves that results from a rare disease thought to afflict about 50,000 people.

Original Article: Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee

NEXT ARTICLE

More From BioPortfolio on "Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...